Etentamig

Multispecific antibody

Also known as ABBV-383

Filedsubmitted

Evidence outlook · regulatory review

Multiple Myeloma: application submitted to FDA

AbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma (2026-10-27). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

CERVINO (NCT06158841): This was a randomized, open-label Phase 3 trial with 421 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-03. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.

Also in development:AL Amyloidosis · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Phase 2/3 (1)
Phase 1/2 (6)
AL Amyloidosis
Multiple Myeloma
NCT07600151 · Universitätsklinikum Hamburg-Eppendorf
2026-12-01 – 2036-12-31 · Myeloma Multiple, Myeloma
What this study did
Other / comorbidity
NCT07420959 · Mayo Clinic
2026-09-30 – 2036-09-30 · Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
What this study did
Phase 1 (5)
Multiple Myeloma

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Etentamig: this drugPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Anselamimab (Amlypave)Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
DaratumumabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
Cizutamig
Phase 1(overall)
Multispecific antibodyBCMA x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication
BirtamimabDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Etentamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-02 · NCT06223516 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 1/2AL AmyloidosisRecruiting
Est. primary completion 2028-02 · NCT06158854 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-08 · NCT05650632 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT06953960 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-02 · NCT07728188 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3AL AmyloidosisNot yet recruiting
Est. primary completion 2034-12 · NCT07793422 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (3)
March 2036 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2036-03 · NCT06896916 · CT.gov ↗
What to watch
September 2036 (2)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
Phase 1/2Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2036-09-30 · NCT07420959 · CT.gov ↗
What to watch
2041 (1)
March 2041 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2041-03 · NCT07095452 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026Filing submittedAbbVie submits a BLA for etentamig in relapsed or refractory multiple myeloma
US, FDA · Source ↗
3 September 2026Topline resultPhase 3 CERVINO meets both primary endpoints (ORR and PFS)
AbbVie · Source ↗